Repirinast

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

Retrieved on: 
Wednesday, November 8, 2023
Standard of care, Patent, Obesity, Laboratory, Fibrosis, Inflammation, CSE, Fatty liver disease, Type, Steatosis, NASH, Risk, UUO, Telmisartan, AGN, NAFLD, CKD, Insulin resistance, Patient, Pharmaceutical industry, Repirinast

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No.
  • The invention claims treating nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company was recently issued a patent from the US patent office for Repirinast in NASH and has also filed corresponding patent applications in Canada, Europe, and China.

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Retrieved on: 
Wednesday, September 6, 2023
Telmisartan, Patent, Steatosis, Insulin resistance, Laboratory, Obesity, CSE, NASH, AGN, Inflammation, UUO, Fibrosis, Algernon, Standard of care, Patient, Risk, Fatty liver disease, Type, NAFLD, CKD, Pharmaceutical industry, Repirinast

11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.”

Key Points: 
  • 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.”
    The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2039, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.
  • “This is the first patent received from the USPTO by Algernon for one of its drugs being investigated under its innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Retrieved on: 
Wednesday, May 31, 2023
Telmisartan, Patent, Asthma, CSE, Heart failure, AGN, Medicine, JPO, Fibrosis, Algernon, Diabetic nephropathy, CKD, Kidney disease, Pharmaceutical industry, Repirinast

The Company has also filed corresponding patent applications in the United States, Canada, Europe and China.

Key Points: 
  • The Company has also filed corresponding patent applications in the United States, Canada, Europe and China.
  • The invention claims the administration of Repirinast, either alone or in combination with telmisartan, for use in the prophylaxis or treatment of renal fibrosis or kidney disease.
  • “This is the first allowance notice received from the JPO by Algernon for one of the drugs being investigated under our innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • “What is also noteworthy, is that Repirinast was originally developed and approved in the Japanese market for the treatment of asthma and so this notice of allowance is even more meaningful.”

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Retrieved on: 
Monday, April 17, 2023
Telmisartan, Patent, Steatosis, Insulin resistance, Laboratory, Obesity, CSE, Heart failure, NASH, United States Patent and Trademark Office, AGN, Medicine, Inflammation, UUO, Fibrosis, Algernon, Standard of care, Patient, Risk, Fatty liver disease, Type, NAFLD, Diabetic nephropathy, CKD, Pharmaceutical industry, Repirinast

The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.

Key Points: 
  • The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.
  • The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing, and formulations, and for new composition of matter patents based on novel salt forms.
  • “This is the first allowance notice received from the USPTO by Algernon for one of the drugs being investigated under our innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Retrieved on: 
Monday, July 11, 2022
Idiopathic pulmonary fibrosis, Blood pressure, Swelling, Kidney, CSE, CKD, Inflammation, US, Engineering, CGMP, DMT, Stroke, Blood, Company, CAGR, AGN, Anemia, Time, Mitsubishi Tanabe Pharma, Kidney disease, Chronic kidney disease, GLOBE, Research, Patient, Fibrosis, Pharmaceutical industry, Repirinast, Telmisartan

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.(the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (CKD) research program with NP-251 (Repirinast).

Key Points: 
  • VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.(the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (CKD) research program with NP-251 (Repirinast).
  • In a pre-clinical animal model of kidney fibrosis, Repirinast reduced fibrosis by 50% with statistical significance.
  • Once completed, the Company plans to begin a small Phase 1 study in Q4, 2022, to determine the bioavailability of its Repirinast finished product.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

Retrieved on: 
Tuesday, April 26, 2022
CSE, NASH, Fibrosis, Laboratory, AGN, Fatty liver disease, GLOBE, Sirius, Pharmaceutical industry, Medical imaging, Repirinast

Repirinast was one of multiple drugs that Algernon screened in a NASH preclinical animal study where liver tissue samples from the Repirinast treatment group underwent a pathology review using sirius red staining.

Key Points: 
  • Repirinast was one of multiple drugs that Algernon screened in a NASH preclinical animal study where liver tissue samples from the Repirinast treatment group underwent a pathology review using sirius red staining.
  • The tissue analysis showed that when compared to the negative control group, Repirinast (60mg/kg QD) reduced fibrosis by 56% (p
  • The Company earlier reported, using the naming protocol NP-251, that Repirinast (30 mg/kg, TID) also reduced fibrosis by 51% vs. untreated controls (p=0.021) in its preclinical animal study of idiopathic pulmonary fibrosis (IPF).
  • In the same study, Ifenprodil (4 mg/kg, TID) showed a 56% reduction in fibrosis vs. untreated controls (p=0.015).

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Mitsubishi Tanabe Pharma, CSE, Asthma, AGN, CKD, Fibrosis, Repirinast, B cell, Chronic kidney disease, Company, LTD, Disease, Acquisition, Immunoglobulin E, Telmisartan, Blood pressure, Patient, Mitsubishi, NASH, Sirius Red, CEO, CGMP, Pharmaceutical industry

Repirinast, in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis conducted by NASH, reduced fibrosis by 50% with statistical significance.

Key Points: 
  • Repirinast, in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis conducted by NASH, reduced fibrosis by 50% with statistical significance.
  • As part of the new CKD research program, the Company will also investigate the use of Repirinast in acute interstitial nephritis.
  • Research conducted in Australia would be reimbursed under the Australian Scientific Research Tax Credit Program at a rate of 43.5%.
  • He conducts an active patient-oriented research program investigating the translational and epidemiological aspects of acute kidney injury (AKI) and other kidney related disorders.